No Prescription |
 |
 | ||
|
VALCIVIR Valtrex |
|
| ||
No Prescription » Prescription Drugs 16 » VALCIVIR Valtrex Valacyclovir is used to treat cold sores (herpes labialis) and shingles (herpes zoster). It is also used to treat genital herpes in patients with normal immune systems. Valacyclovir can also be used to control genital herpes outbreaks in all patients including those with HIV. This is also known as suppressive therapy. This medication helps control symptoms but does not cure the disease.Valacyclovir belongs to a class of medications known as antivirals.If you are taking valacyclovir for treatment of genital herpes it is important to follow safe sex practices to lower the chance of giving herpes to your partner even if there are no symptoms present. Always use a condom made of latex or polyurethane. When you have symptoms or are experiencing an outbreak do not have sexual contact with your partner.OTHER USES: This section contains uses of this drug that are not listed in the approved professional labeling for the drug but that may be prescribed by your health care professional. Use this drug for a condition that is listed in this section only if it has been so prescribed by your health care professional.This medication may be used to prevent or treat other types of viral infections (cytomegalovirus) in certain patient populations.How to use Valacyclovir OralRead the Patient Information Leaflet available from your pharmacist. Consult your doctor or pharmacist if you have any questions.Take valacyclovir by mouth with or without food or as directed by your doctor. Drink plenty of fluids while taking this medication. When taking this medication to treat an outbreak it works best if you take this medication when you first notice an outbreak is starting. The medication may not work as well if you wait more than 72 hours to start it. Dosage is based on your medical condition and response to therapy.When treating an outbreak continue to take this medication until the full-prescribed amount is finished even if symptoms disappear. When using this drug to suppress/control outbreaks take exactly as directed by your doctor. Do not skip doses or stop taking this without your doctor's approval. Stopping therapy too soon may result in ineffective treatment.If using this medication to treat an outbreak inform your doctor if your condition persists or worsens. Buy VALCIVIR Valtrex and other Prescription Drugs 16 products online at Medstore. Buy Online at Medstore - Click Here!
About VALCIVIR Valtrex: Product Type: Prescription Drugs 16 VALCIVIR ( Valtrex Generic Valacyclovir ) VALCIVIR (Valtrex Generic Valacyclovir) Valtrex Generic Valacyclovir 1000 mg Valtrex Generic Valacyclovir VALCIVIR
View more Prescription Drugs 16 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
